No Data
No Data
Sellas Falls 17% Amid Phase 3 Study Update for Galinpepimut-S
Express News | Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion by 2029 as Clinical Trials Increase
Express News | SELLAS Life Sciences Announced Review Of Ongoing Phase 3 REGAL Clinical Trial Of Galinpepimut-S In Acute Myeloid Leukemia By IDMC
Express News | Sellas Life Sciences Group Inc - Independent Data Monitoring Committee (Idmc) Recommends Continuation of Phase 3 Regal Trial Without Any Modifications
Express News | Sellas Life Sciences Group Inc: No Safety or Futility Concerns Were Raised Based on Efficacy and Safety Assessment of All Regal Patients
Express News | Sellas Life Sciences Group Inc - Interim Analysis Anticipated by Q4 2024
No Data
Traders Cap Ayam : How much floating?